CAN UNDERDOG GSK SCULPT ITSELF INTO A CHAMPION? (BUY, 33% UPSIDE)
04/11/26 -" "If a man knows not to which port he sails, no wind is favourable." The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) longer-term shareholders, the ultimate victim of their ..."
Pages
72
Language
English
Published on
04/11/26
You may also be interested by these reports :
04/11/26
The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being ...
04/11/26
“If a man knows not to which port he sails, no wind is favourable.” The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) ...
04/11/26
BioNTech’s Q3 operational performance exceeded expectations, driven by higher outlicensing sales from Bristol-Myers Squibb. 2026 sales guidance was ...
03/11/26
The Q3 results were reassuring, as growth in subcutaneous immunoglobulins, higher volumes and plasma cost optimisation aided expansion in top-line as ...